FDA (CDER)
GUIDANCE DRAFT
Development of Non-Opioid Analgesics for Acute Pain
Published: 5/13/2026Detected: 5/13/2026
Summary preview
Development of Non-Opioid Analgesics for Acute Pain draft guidance is intended to shape how sponsors design and justify non-opioid acute pain programs, with particular emphasis on the clinical evidence needed to support…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountneurology
pediatrics
#acute pain
#non-opioid analgesics
#clinical trials
#efficacy endpoints
#adverse events
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026